[1]崔文君.血管紧张素Ⅱ受体拮抗剂联合中成药治疗 慢性肾炎蛋白尿的研究进展[J].医学信息,2018,31(17):45-48.[doi:10.3969/j.issn.1006-1959.2018.17.015]
 CUI Wen-jun.Advances in Research of Angiotensin II Receptor Antagonist Combined with Chinese Patent Medicine in the Treatment of Chronic Nephritis Proteinuria[J].Journal of Medical Information,2018,31(17):45-48.[doi:10.3969/j.issn.1006-1959.2018.17.015]
点击复制

血管紧张素Ⅱ受体拮抗剂联合中成药治疗 慢性肾炎蛋白尿的研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年17期
页码:
45-48
栏目:
综述
出版日期:
2018-09-01

文章信息/Info

Title:
Advances in Research of Angiotensin II Receptor Antagonist Combined with Chinese Patent Medicine in the Treatment of Chronic Nephritis Proteinuria
文章编号:
1006-1959(2018)17-00450-04
作者:
崔文君
首都医科大学燕京医学院,北京 101300
Author(s):
CUI Wen-jun
Yanjing Medical College,Capital Medical University,Beijing 101300,China
关键词:
血管紧张素Ⅱ受体拮抗剂中成药慢性肾炎蛋白尿
Keywords:
Key words:Angiotensin II receptor antagonistChinese patent medicineChronic nephritis proteinuria
分类号:
R473.6
DOI:
10.3969/j.issn.1006-1959.2018.17.015
文献标志码:
A
摘要:
慢性肾炎基本临床表现为蛋白尿、血尿、高血压、水肿,其中蛋白尿是加速肾小球硬化、促进肾功能恶化的重要因素之一,且蛋白尿水平越高,导致肾脏病进展的速度越快,因此积极降低蛋白尿是肾脏病治疗的关键。血管紧张素Ⅱ受体拮抗剂除降压作用外,还有降低患者蛋白尿水平及肾脏保护作用,为进一步减少慢性肾炎蛋白尿,在应用ARB基础上加用中成药亦可获得疗效进行综述。
Abstract:
Abstract:The basic clinical manifestations of chronic glomerulonephritis are proteinuria,hematuria,hypertension,edema,among which proteinuria is one of the important factors to accelerate glomerulosclerosis and promote the deterioration of renal function,and the higher the level of proteinuria,the faster the progress of kidney disease.Therefore,active reduction of proteinuria is the key to the treatment of kidney disease.Angiotensin II receptor antagonists,in addition to antihypertensive effect,also reduce the level of proteinuria and renal protection in patients,in order to further reduce chronic nephritis proteinuria,the use of ARB based on the addition of proprietary Chinese medicine can also be obtained.

参考文献/References:

[1]张承承,任可.蛋白尿的中西医治疗方法概述[J].现代中医临床,2014,21(3):1-5. [2]Liakos CI,Vyssoulis GP,Markou MI,et al.Twenty-Four-Hour Urine ±1 -Microglobulin as a Marker of Hypertension-Induced Renal Impairment and Its Response on Different Blood Pressure-Lowering Drugs[J].Journal of Clinical Hypertension,2016,18(10):1000-1006. [3]张福霞,刘海霞,陈文峰.血管紧张素Ⅱ受体拮抗剂防治老年糖尿病肾病研究进展[J].中国老年学杂志,2015,35(15):4409-4411. [4]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:473-529. [5]Disease K.Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Polskie Archiwum Medycyny Wewntrznej,2013,120(7-8):300-306. [6]陈孜瑾,陈晓农.血管紧张素Ⅱ受体拮抗剂降蛋白尿及肾脏保护研究进展[J].肾脏病与透析肾移植杂志,2017,26(5):467-470. [7]肇丁.氯沙坦钾片联合肾炎康复片治疗慢性肾小球肾炎蛋白尿的疗效观察[J].中国药物经济学,2017(8):87-89. [8]郑宝林,李婷,余俊文,等.肾炎康复片联合氯沙坦钾治疗慢性肾炎的疗效观察[J].广州中医药大学学报,2014,31(1):32-34. [9]朱磊,吴娅琳,敖利娜,等.肾炎康复片联合氯沙坦钾治疗原发性IgA肾病的临床疗效分析[J].医药前沿,2016,6(31): 191-192. [10]杨素霞,陈宝平,陈方,等.不同严重程度IgA肾病患者血管内皮细胞生长因子和内皮缩血管肽-1水平的变化及意义[J].广东医学,2015,36(24):3819-3822. [11]何艳,郭爱莉,陶晓岚.百令胶囊联合氯沙坦钾治疗慢性肾小球肾炎的临床研究[J].现代药物与临床,2018,33(4):903-907. [12]黄艳芳.百令胶囊对糖尿病肾病患者肾功能的影响观察[J].海峡药学,2015,27(8):105-106. [13]杜渊,杜浩昌,李春庆,等.百令胶囊对维持性血液透析患者30例炎症与营养不良的观察[J].中国中西医结合肾病杂志,2015,16(5):428-430. [14]王光辉.坎地沙坦联合黄葵胶囊治疗慢性肾炎蛋白尿的临床疗效观察[J].现代诊断与治疗,2014,25(22):5126-5127. [15]梁宏明,梁儒信,廖伟.缬沙坦和雷公藤多苷联合治疗慢性肾小球肾炎蛋白尿的效果[J].临床医学工程,2015,22(7):887-888. [16]王宇,延佩,程小红.肾复康Ⅱ号方联合氯沙坦钾治疗慢性肾小球肾炎30例临床观察[J].云南中医中药杂志,2015,36(1):44-46. [17]沈卫强,施颖.健脾益肾颗粒联合氯沙坦降低慢性肾小球肾炎蛋白尿及肾功能保护作用的临床观察[J].中国中医药科技,2013,20(1):62-63. [18]周静,魏昕,曾艳,等.氯沙坦钾联合益肾化湿颗粒治疗慢性肾小球肾炎的临床疗效及安全性评价[J].中国临床药理学杂志,2016,32(4):297-299. [19]许路军,兰义成,连晓江,等.正清风痛宁缓释片联合厄贝沙坦治疗慢性肾炎蛋白尿30例临床观察[J].国医论坛,2015,30(4):43-44. [20]刘星宇,黄寻知,姚子睿.益气固摄浓缩丸联合替米沙坦治疗脾肾气虚型慢性肾炎蛋白尿疗效观察[J].医学信息,2017,30(1):152. [21]Kim SM,Lee CH,Lee JP,et al.The association between albumin to creatinine ratio and total protein to creatinine ratio in patients with chronic kidney disease[J].Clin Nephrol,2012,78(5):346-352. [22]王东,王亿平.参地颗粒联合氯沙坦钾治疗慢性肾炎蛋白尿的临床研究[J].陕西中医学院学报,2015,38(1):39-40. [23]刘向东,艾子敏,张燕,等,慢性肾小球肾炎患者血清MMP-9和TIMP-1的浓度及意义[J].现代生物医学进展,2014,14(31):6129-6134. [24]李晓宁,王向荣.复方石韦颗粒联合缬沙坦和前列地尔治疗慢性肾小球肾炎的临床研究[J].现代药物与临床,2016,31(10)1628-1631. [25]陈华,朱激扬,蒋坚锋.白芍总苷联合缬沙坦治疗慢性肾小球肾炎临床观察[J].中国医院药学,2016,36(8):79. [26]陈爱民.厄贝沙坦联合银杏叶滴丸治疗早期慢性肾脏病疗效观察[J].齐齐哈尔医学院学报,2015,36(12):1762-1763. [27]郭斌.中医药治疗肾性蛋白尿的研究进展[J].内蒙古中医药,2015,3:97-98.

相似文献/References:

[1]雷丽霞,李瑞林,苏 阳,等.中成药在肺癌中的应用现状[J].医学信息,2022,35(24):173.[doi:10.3969/j.issn.1006-1959.2022.24.039]
 LEI Li-xia,LI Rui-lin,SU Yang,et al.Application Status of Chinese Patent Medicine in Lung Cancer[J].Journal of Medical Information,2022,35(17):173.[doi:10.3969/j.issn.1006-1959.2022.24.039]
[2]施 弘,李云攀,李秀芬,等.日常性中医疗法智能咨询系统设计思路[J].医学信息,2021,34(20):25.[doi:10.3969/j.issn.1006-1959.2021.20.006]
 SHI Hong,LI Yun-pan,LI Xiu-fen,et al.The Design Thoughts of Intelligent Consultation System of Daily Chinese Medicine Therapy[J].Journal of Medical Information,2021,34(17):25.[doi:10.3969/j.issn.1006-1959.2021.20.006]
[3]陈孝辉.慢性阻塞性肺气肿的中医药治疗研究[J].医学信息,2022,35(05):60.[doi:10.3969/j.issn.1006-1959.2022.05.015]
 CHEN Xiao-hui.Study on TCM Treatment of Chronic Obstructive Pulmonary Emphysema[J].Journal of Medical Information,2022,35(17):60.[doi:10.3969/j.issn.1006-1959.2022.05.015]
[4]王 甲,刘荣梅,杨肖沫,等.基于倾向指数匹配法的ARB类两种降压药物的成本-效果分析[J].医学信息,2023,36(16):84.[doi:10.3969/j.issn.1006-1959.2023.16.015]
 WANG Jia,LIU Rong-mei,YANG Xiao-mo,et al.Cost-effectiveness Analysis of Two Kinds of ARB Antihypertensive Drugs Based on Propensity Score Matching Method[J].Journal of Medical Information,2023,36(17):84.[doi:10.3969/j.issn.1006-1959.2023.16.015]
[5]熊 鹰.中医疗法在慢性萎缩性胃炎治疗中的研究现状[J].医学信息,2023,36(23):189.[doi:10.3969/j.issn.1006-1959.2023.23.047]
 XIONG Ying.Research Status of Traditional Chinese Medicine Therapy for Chronic Atrophic Gastritis[J].Journal of Medical Information,2023,36(17):189.[doi:10.3969/j.issn.1006-1959.2023.23.047]

更新日期/Last Update: 2018-09-01